These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

839 related articles for article (PubMed ID: 22338670)

  • 21. Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.
    Zareba W; Daubert JP; Beck CA; Huang DT; Alexis JD; Brown MW; Pyykkonen K; McNitt S; Oakes D; Feng C; Aktas MK; Ayala-Parades F; Baranchuk A; Dubuc M; Haigney M; Mazur A; McPherson CA; Mitchell LB; Natale A; Piccini JP; Raitt M; Rashtian MY; Schuger C; Winters S; Worley SJ; Ziv O; Moss AJ;
    J Am Coll Cardiol; 2018 Aug; 72(6):636-645. PubMed ID: 30071993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes in patients with sustained ventricular tachyarrhythmias occurring within 48 h of acute myocardial infarction: when is ICD appropriate?
    Liang JJ; Hodge DO; Mehta RA; Russo AM; Prasad A; Cha YM
    Europace; 2014 Dec; 16(12):1759-66. PubMed ID: 25100756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial.
    Kloppe A; Proclemer A; Arenal A; Lunati M; Martìnez Ferrer JB; Hersi A; Gulaj M; Wijffels MC; Santi E; Manotta L; Mangoni L; Gasparini M
    Circulation; 2014 Jul; 130(4):308-14. PubMed ID: 24838360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
    Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
    J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends in treated ventricular fibrillation out-of-hospital cardiac arrest: a 17-year population-based study.
    Bunch TJ; White RD; Friedman PA; Kottke TE; Wu LA; Packer DL
    Heart Rhythm; 2004 Sep; 1(3):255-9. PubMed ID: 15851165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis.
    Aizer A; Stern EH; Gomes JA; Teirstein AS; Eckart RE; Mehta D
    Am J Cardiol; 2005 Jul; 96(2):276-82. PubMed ID: 16018857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of cardiovascular magnetic resonance in patients with biopsy-proven systemic sarcoidosis.
    Flamée L; Symons R; Degtiarova G; Dresselaers T; Gheysens O; Wuyts W; Van Cleemput J; Bogaert J
    Eur Radiol; 2020 Jul; 30(7):3702-3710. PubMed ID: 32166494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Temporal trends and long term follow-up of implantable cardioverter defibrillator therapy for secondary prevention: A 15-year single-centre experience.
    Caputo ML; Regoli F; Conte G; Adjibodou B; Svab S; Del Bufalo A; Moccetti T; Curti M; Klersy C; Auricchio A
    Int J Cardiol; 2017 Feb; 228():31-36. PubMed ID: 27863358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antitachyarrhythmic interventions of implantable cardioverter-defibrillator in primary and secondary sudden cardiac death prevention patients].
    Piekarz J; Rydlewska A; Majewski J; Lelakowski J
    Pol Merkur Lekarski; 2012 Jun; 32(192):368-73. PubMed ID: 22891561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Programming antitachycardia pacing for primary prevention in patients with implantable cardioverter defibrillators: results from the PROVE trial.
    Saeed M; Neason CG; Razavi M; Chandiramani S; Alonso J; Natarajan S; Ip JH; Peress DF; Ramadas S; Massumi A
    J Cardiovasc Electrophysiol; 2010 Dec; 21(12):1349-54. PubMed ID: 20561107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease.
    Martinelli M; de Siqueira SF; Sternick EB; Rassi A; Costa R; Ramires JA; Kalil Filho R
    Am J Cardiol; 2012 Oct; 110(7):1040-5. PubMed ID: 22727179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between statin use and mortality in patients with implantable cardioverter-defibrillators and left ventricular systolic dysfunction.
    Coleman CI; Kluger J; Bhavnani S; Clyne C; Yarlagadda R; Guertin D; White CM
    Heart Rhythm; 2008 Apr; 5(4):507-10. PubMed ID: 18362016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ventricular tachyarrhythmia recurrence in primary versus secondary implantable cardioverter-defibrillator patients and role of electrophysiology study.
    Zaman S; Sivagangabalan G; Chik W; Stafford W; Hayes J; Denman R; Young G; Sanders P; Kovoor P
    J Interv Card Electrophysiol; 2014 Dec; 41(3):195-202. PubMed ID: 25267274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
    Roses-Noguer F; Jarman JW; Clague JR; Till J
    Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with prophylactic cardioverter-defibrillator therapy.
    Grimm W; Plachta E; Maisch B
    Pacing Clin Electrophysiol; 2006 Jul; 29(7):759-64. PubMed ID: 16884513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early Implantation of Primary Prevention Implantable Cardioverter Defibrillators for Patients with Newly Diagnosed Severe Nonischemic Cardiomyopathy.
    Voskoboinik A; Bloom J; Taylor A; Mariani J
    Pacing Clin Electrophysiol; 2016 Sep; 39(9):992-8. PubMed ID: 27343008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Normalization of Left Ventricular Ejection Fraction and Incidence of Appropriate Antitachycardia Therapy in Patients With Implantable Cardioverter Defibrillator for Primary Prevention of Sudden Death.
    House CM; Nguyen D; Thomas AJ; Nelson WB; Zhu DW
    J Card Fail; 2016 Feb; 22(2):125-32. PubMed ID: 26522819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of high-rate cutoff and long detection interval ICD programming in secondary prevention patients.
    Hayashi Y; Takagi M; Kakihara J; Sakamoto S; Doi A; Sugioka K; Hanatani A; Yoshiyama M
    Heart Vessels; 2017 Feb; 32(2):175-185. PubMed ID: 27259484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.